Figure 3
Bcl-xLIEC-KO and control mice in an inflammation-driven model for intestinal carcinogenesis. (a) Schematic treatment course with intraperitoneal injection of AOM at the start day and three cycles of DSS in the drinking water (2% w/v). (b) Diarrhea severity and weight loss after DSS administration (red arrow) and during recovery time (blue arrow). Exemplarily shown for the third DSS cycle. (c) Endoscopic images of Bcl-xLIEC-KO and control mice. The dashed line shows a neoplastic lesion. (d) The determination of tumor number (P=0.03) and size (P=0.008) at the end of treatment shows a significantly lower tumor burden in Bcl-xLIEC-KO compared with control mice. Furthermore, the BMI is higher in Bcl-xLIEC-KO mice (P=0.0003). Values are expressed as means+S.D. Control mice: n=8; Bcl-xLIEC-KO mice: n=9. *P<0.05; **P<0.01; ***P<0.001
